RT Journal Article
SR Electronic
T1 Genetic variation near CXCL12 is associated with susceptibility to HIV-related non-Hodgkin lymphoma
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 19011999
DO 10.1101/19011999
A1 Christian W. Thorball
A1 Tiphaine Oudot-Mellakh
A1 Christian Hammer
A1 Federico A. Santoni
A1 Jonathan Niay
A1 Dominique Costagliola
A1 Cécile Goujard
A1 Laurence Meyer
A1 Sophia S. Wang
A1 Shehnaz K. Hussain
A1 Ioannis Theodorou
A1 Matthias Cavassini
A1 Andri Rauch
A1 Manuel Battegay
A1 Matthias Hoffmann
A1 Patrick Schmid
A1 Enos Bernasconi
A1 Huldrych F. Günthard
A1 Paul J. McLaren
A1 Charles S. Rabkin
A1 Caroline Besson
A1 Jacques Fellay
YR 2019
UL http://medrxiv.org/content/early/2019/11/15/19011999.abstract
AB Human immunodeficiency virus (HIV) infection is associated with a substantially increased risk of non-Hodgkin lymphoma (NHL). High plasma viral load, low CD4+ T cell counts and absence of antiretroviral treatment (ART) are known predictive factors for NHL. Even in the era of suppressive ART, HIV-infected individuals remain at increased risk of developing NHL compared to the general population. To search for human genetic determinants of HIV-associated NHL, we performed case-control genome-wide association studies (GWAS) in three cohorts of HIV+ patients of European ancestry and meta-analyzed the results. In total, 278 cases and 1924 matched controls were included. We observed a significant association with NHL susceptibility in the C-X-C motif chemokine ligand 12 (CXCL12) region on chromosome 10. A fine mapping analysis identified rs7919208 as the most likely causal variant (P = 4.77e-11). The G>A polymorphism creates a new transcription factor binding site for BATF and JUND. Analyses of topologically associating domains and promoter capture Hi-C data revealed significant interactions between the rs7919208 region and the promoter of CXCL12, also known as stromal-derived factor 1 (SDF-1). These results suggest a modulatory role of CXCL12 regulation in the increased susceptibility to NHL observed in the HIV-infected population.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study has been financed within the framework of the Swiss HIV Cohort Study, supported by the Swiss National Science Foundation (grant #177499), by SHCS project #789 and by the SHCS research foundation. This work further benefited from the ANRS funding of both the Primo and Lymphovir cohorts. The GWAS of NHL project was supported by the intramural program of the Division of Cancer Epidemiology and Genetics (DCEG), National Cancer Institute (NCI), National Institutes of Health (NIH).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesFull summary statistics can be found in the GWAS catalog (https://www.ebi.ac.uk/gwas). The raw genotype data can be obtained through the respective cohorts.